asurgeryАмбулаторная хирургияAmbulatornaya khirurgiya = Ambulatory Surgery (Russia)2712-87412782-2591ООО «ГРУППА РЕМЕДИУМ»asurgery-61Research ArticleПРАКТИКА | ОБМЕН ОПЫТОМSHARING EXPERIENCES | PRACTICEВторичная профилактика острого венозного тромбоза. Современные тенденцииSecondary prevention of acute venous thrombosis. Modern trendsБогачевВ. Ю.BogachevV. Y.noemail@neicon.ruБолдинБ. В.BoldinB. V.noemail@neicon.ruДженинаО. В.DzheninaO. V.noemail@neicon.ruЛобановВ. Н.LobanovV. N.noemail@neicon.ruРоссийский национальный исследовательский медицинский университет им. Н.И. ПироговаРоссияPirogov Russian Scientific and Research Medical UniversityRussian FederationПервый Флебологический ЦентрРоссияPirogov Russian Scientific and Research Medical UniversityRussian FederationПервый Флебологический ЦентрРоссияFirst Phlebologic CenterRussian Federation20163012201603-45662Copyright © Богачев В.Ю., Болдин Б.В., Дженина О.В., Лобанов В.Н., 20162016Богачев В.Ю., Болдин Б.В., Дженина О.В., Лобанов В.Н.Bogachev V.Y., Boldin B.V., Dzhenina O.V., Lobanov V.N.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.a-surgeon.ru/jour/article/view/61

Венозные тромбоэмболические осложнения (ВТЭО), включающие тромбоз глубоких вен (ТГВ) и тромбоэмболию легочной артерии (ТЭЛА), являются достаточно частыми, но предупреждаемыми состояниями. В индустриально развитых странах регистрируют 1-2 новых случая ВТЭО на 1 000 человек в год. В США ежегодно ВТЭО переносят 900 тыс. пациентов. Причем приведенные цифры, скорее всего, занижены, т.к. в силу размытости клинической картины и недостаточной чувствительности скрининг-тестов частота верифицированных ВТЭО не превышает 60-70% [1, 2]. Согласно международным рекомендациям и стандартам больным с ВТЭО показана антико-агулянтная терапия, ее длительность определяется соотношением риска рецидива ВТЭО и риска кровотечений.

Venous thromboembolic complications (VTC) including deep veins thrombosis and pulmonary artery thromboembolia are sufficiently frequent but preventable states. In industrially developed countries 1-2 cases of VTC per 1 thousand persons per year are registered. In USA 900 thousand patients suffer from VTC annually. But these figures are most likely conservative as due to diffuseness of a clinical pattern and insufficient sensitivity of screening tests the frequency of verified VTC doesn't exceed 60-70% [1, 2].

венозные тромбоэмболические осложненияфакторы рискаантикоагулянтная терапиясулодексидvenous thrombolic complicationsrisk factorsanticoagulant therapySulodexideReferencesKyrLe P, Eichinger S. Deep vein thrombosis. Lancet, 2005, 365: 1163-1174.KyrLe P, Eichinger S. Deep vein thrombosis. Lancet, 2005, 365: 1163-1174.Tapson V. Acute pulmonary embolism. N Engl J Med, 2008, 358: 1163-1174.Tapson V. Acute pulmonary embolism. N Engl J Med, 2008, 358: 1163-1174.SchuLman S, Lindmarker P, HoLmstrom M et aL. Postthrombotic syndrome, recurrence, and death 10 years after the first episode of venous thromboembolism treated with warfarin for 6 weeks or 6 months. J Thromb Haemost, 2006, 4: 734-742.SchuLman S, Lindmarker P, HoLmstrom M et aL. Postthrombotic syndrome, recurrence, and death 10 years after the first episode of venous thromboembolism treated with warfarin for 6 weeks or 6 months. J Thromb Haemost, 2006, 4: 734-742.Pesavento R, Bernardi E, ConcoLato A et aL. Postthrombotic syndrome. Semin Thromb Hemos, 2006, 32: 744-751.Pesavento R, Bernardi E, ConcoLato A et aL. Postthrombotic syndrome. Semin Thromb Hemos, 2006, 32: 744-751.McKean SC, DeiteLzweig SB, Sasahara A, Michota F, Jacobson A. Assessing the risk of venous thromboemboLism and identifying barriers to thromboprophyLaxis in the hospitaLized patient. Hosp Med, 2009, 4(8 SuppL): 1-7.McKean SC, DeiteLzweig SB, Sasahara A, Michota F, Jacobson A. Assessing the risk of venous thromboemboLism and identifying barriers to thromboprophyLaxis in the hospitaLized patient. Hosp Med, 2009, 4(8 SuppL): 1-7.Zhu T, Martinez I, Emmerich J. Venous thromboemboLism: risk factors for recurrence. Arterioscler Thromb Vasc Biol, 2009, 29: 298-310.Zhu T, Martinez I, Emmerich J. Venous thromboemboLism: risk factors for recurrence. Arterioscler Thromb Vasc Biol, 2009, 29: 298-310.Weitz JI. Unanswered questions in venous thromboemboLism. Thrombosis Res, 2009, 123(SuppL 4): 2-10.Weitz JI. Unanswered questions in venous thromboemboLism. Thrombosis Res, 2009, 123(SuppL 4): 2-10.Nishioka J, Goodin S. Low-moLecuLar-weight heparin in cancerassociated thrombosis: treatment, secondary prevention, and survivaL. J Oncol Pharm Pract, 2007, 13: 85-97.Nishioka J, Goodin S. Low-moLecuLar-weight heparin in cancerassociated thrombosis: treatment, secondary prevention, and survivaL. J Oncol Pharm Pract, 2007, 13: 85-97.Laux V, Perzborn E, Heitmeier S, et aL. Direct inhibitors of coagusurvivaL. J Oncol Pharm Pract, 2007, 13: 85-97.Laux V, Perzborn E, Heitmeier S, et aL. Direct inhibitors of coagusurvivaL. J Oncol Pharm Pract, 2007, 13: 85-97.Lation proteins - the end of the heparin and Low-moLecuLarweight heparin era for anticoaguLant therapy? Thromb Haemost, 2009, 102: 892-899.Lation proteins - the end of the heparin and Low-moLecuLarweight heparin era for anticoaguLant therapy? Thromb Haemost, 2009, 102: 892-899.Spinler SA, Wittkowsky AK, Nutescu EA, Smythe MA. Anticoagulation monitoring part 2: unfractionated heparin and low-molecular-weight heparin. Ann Pharmacother, 2005, 39: 1275-1285.Spinler SA, Wittkowsky AK, Nutescu EA, Smythe MA. Anticoagulation monitoring part 2: unfractionated heparin and low-molecular-weight heparin. Ann Pharmacother, 2005, 39: 1275-1285.Lee AY. The effects of low molecular weight heparins on venous thromboembolism and survival in patients with cancer. Thromb Res., 2007, 120(Suppl 2): 121-127.Lee AY. The effects of low molecular weight heparins on venous thromboembolism and survival in patients with cancer. Thromb Res., 2007, 120(Suppl 2): 121-127.Wittkowsky AK. New oral anticoagulants: a practical guide for clinicians. J Thromb Thrombolysis, 2010, 29: 182-191.Wittkowsky AK. New oral anticoagulants: a practical guide for clinicians. J Thromb Thrombolysis, 2010, 29: 182-191.Douketis JD, Gu CS, Schulman S, Ghirarduzzi A, Pengo V, Prandoni P. The risk for fatal pulmonary embolism after discontinuing anticoagulant therapy for venous thromboembolism. Ann Intern Med, 2007, 147: 766-774.Douketis JD, Gu CS, Schulman S, Ghirarduzzi A, Pengo V, Prandoni P. The risk for fatal pulmonary embolism after discontinuing anticoagulant therapy for venous thromboembolism. Ann Intern Med, 2007, 147: 766-774.Agnelli G, Becattini C. Treatment of DVT: How long is enough and how do you predict recurrence. J Thromb Thrombolysis, 2008, 25: 37-44.Agnelli G, Becattini C. Treatment of DVT: How long is enough and how do you predict recurrence. J Thromb Thrombolysis, 2008, 25: 37-44.Schulman S. Extension of anticoagulation after venous thromboembolism. Risk factors influencing the decision. Hamostaseologie, 2008, 28: 110-119.Schulman S. Extension of anticoagulation after venous thromboembolism. Risk factors influencing the decision. Hamostaseologie, 2008, 28: 110-119.McRae S, Tran H, Schulman S,Ginsberg J, Kearon C. Effect of patient's sex on risk of recurrent venous thromboembolism: a meta-analysis. Lancet, 2006, 368: 371-378.McRae S, Tran H, Schulman S,Ginsberg J, Kearon C. Effect of patient's sex on risk of recurrent venous thromboembolism: a meta-analysis. Lancet, 2006, 368: 371-378.Kyrle PA, Minar E, Bialonczyk C, Hirschl M, Weltermann A, Eichinger S. The risk of recurrent venous thromboembolism in men and women. N Engl J Med, 2004, 350: 2558-2563.Kyrle PA, Minar E, Bialonczyk C, Hirschl M, Weltermann A, Eichinger S. The risk of recurrent venous thromboembolism in men and women. N Engl J Med, 2004, 350: 2558-2563.White RH, Dager WE, Zhou H, Murin S. Racial and gender differences in the incidence of recurrent venous thromboembolism. Thromb Haemost, 2006, 96: 267-273. 19^gren M, Eriksson H, Bergqvist D, Sternby NH. Subcutaneous fat accumulation and BMI associated with risk for pulmonary embolism in patients with proximal deep vein thrombosis: a population study based on 23 796 consecutive autopsies. J Intern Med, 2005, 258: 166-171.White RH, Dager WE, Zhou H, Murin S. Racial and gender differences in the incidence of recurrent venous thromboembolism. Thromb Haemost, 2006, 96: 267-273. 19^gren M, Eriksson H, Bergqvist D, Sternby NH. Subcutaneous fat accumulation and BMI associated with risk for pulmonary embolism in patients with proximal deep vein thrombosis: a population study based on 23 796 consecutive autopsies. J Intern Med, 2005, 258: 166-171.Christiansen SC, Cannegieter SC, Koster T, Vandenbroucke JP, Rosendaal FR. Thrombophilia, clinical factors, and recurrent venous thrombotic events. JAMA, 2005, 293: 2352-2361.Christiansen SC, Cannegieter SC, Koster T, Vandenbroucke JP, Rosendaal FR. Thrombophilia, clinical factors, and recurrent venous thrombotic events. JAMA, 2005, 293: 2352-2361.Verhovsek M, Douketis JD, Yi Q, et al. Systematic review: D-dimer to predict recurrent disease after stopping anticoagulant therapy for unprovoked venous thromboembolism. Ann Intern Med, 2008, 149: 481-490.Verhovsek M, Douketis JD, Yi Q, et al. Systematic review: D-dimer to predict recurrent disease after stopping anticoagulant therapy for unprovoked venous thromboembolism. Ann Intern Med, 2008, 149: 481-490.Cosmi B, Legnani C, Cini M, Guazzaloca G, Palareti G. D-dimer levels in combination with residual venous obstruction and the risk of recurrence after anticoagulation withdrawal for a first idiopathic deep vein thrombosis. Thromb Haemost, 2005, 94: 969-974.Cosmi B, Legnani C, Cini M, Guazzaloca G, Palareti G. D-dimer levels in combination with residual venous obstruction and the risk of recurrence after anticoagulation withdrawal for a first idiopathic deep vein thrombosis. Thromb Haemost, 2005, 94: 969-974.Eichinger S, Heinze G, Jandeck LM, Kyrle PA. Risk assessment of recurrence in patients with unprovoked deep vein thrombosis or pulmonary embolism: the Vienna prediction model. Circulation, 2010, 121(14): 1630-1636.Eichinger S, Heinze G, Jandeck LM, Kyrle PA. Risk assessment of recurrence in patients with unprovoked deep vein thrombosis or pulmonary embolism: the Vienna prediction model. Circulation, 2010, 121(14): 1630-1636.Tosetto A, Iorio A, Marcucci M, Baglin T, Cushman M, Eichinger S, Palareti G, Poli D, Tait RC, Douketis J. Predicting disease recurrence in patients with previous unprovoked venous thromboem-bolism: a proposed prediction score (DASH). J Thrombol Haemost, 2012, 10(6): 1019-1025.Tosetto A, Iorio A, Marcucci M, Baglin T, Cushman M, Eichinger S, Palareti G, Poli D, Tait RC, Douketis J. Predicting disease recurrence in patients with previous unprovoked venous thromboem-bolism: a proposed prediction score (DASH). J Thrombol Haemost, 2012, 10(6): 1019-1025.Siragusa S, Malato A, Anastasio R et al. Residual vein thrombosis to establish duration of anticoagulation after a first episode of deep vein thrombosis: the Duration of Anticoagulation based on Compression UltraSonography (DACUS) study. Blood, 2008, 112: 511-515.Siragusa S, Malato A, Anastasio R et al. Residual vein thrombosis to establish duration of anticoagulation after a first episode of deep vein thrombosis: the Duration of Anticoagulation based on Compression UltraSonography (DACUS) study. Blood, 2008, 112: 511-515.Ageno W, Becattini C, Brighton T, Selby R, Kamphuisen PW. Cardiovascular risk factors and venous thromboembolism: a meta-analysis. Circulation, 2008, 117: 93-102.Ageno W, Becattini C, Brighton T, Selby R, Kamphuisen PW. Cardiovascular risk factors and venous thromboembolism: a meta-analysis. Circulation, 2008, 117: 93-102.Eichinger S, Hron G, Bialonczyk C et al. Overweight, obesity, and the risk of recurrent venous thromboembolism. Arch Intern Med, 2008, 168: 1678-1683.Eichinger S, Hron G, Bialonczyk C et al. Overweight, obesity, and the risk of recurrent venous thromboembolism. Arch Intern Med, 2008, 168: 1678-1683.Besser M, Baglin C, Luddington R, van Hylckama Vlieg A, Baglin T. High rate of unprovoked recurrent venous thrombosis is associated with high thrombin-generating potential in a prospective cohort study. J Thromb Haemost, 2008, 6: 17201725.Besser M, Baglin C, Luddington R, van Hylckama Vlieg A, Baglin T. High rate of unprovoked recurrent venous thrombosis is associated with high thrombin-generating potential in a prospective cohort study. J Thromb Haemost, 2008, 6: 17201725.Tripodi A, Legnani C, Chantarangkul V, Cosmi B, Palareti G, Mannucci PM. High thrombin generation measured in the presence of thrombomodulin is associated with an increased risk of recurrent venous thromboembolism. J Thromb Haemost, 2008, 6: 1327-1333.Tripodi A, Legnani C, Chantarangkul V, Cosmi B, Palareti G, Mannucci PM. High thrombin generation measured in the presence of thrombomodulin is associated with an increased risk of recurrent venous thromboembolism. J Thromb Haemost, 2008, 6: 1327-1333.Ho WK, Hankey GJ, Quinlan DJ, Eikelboom JW. Risk of recurrent venous thromboembolism in patients with common thrombophilia: a systematic review. Arch Intern Med, 2006, 166: 729-736.Ho WK, Hankey GJ, Quinlan DJ, Eikelboom JW. Risk of recurrent venous thromboembolism in patients with common thrombophilia: a systematic review. Arch Intern Med, 2006, 166: 729-736.Marchiori A, Mosena L, Prins MH, Prandoni P. The risk of recurrent venous thromboembolism among heterozygous carriers of factor V Leiden or prothrombin G20210A mutation. A systematic review of prospective studies. Haematologica, 2007, 92: 11071114.Marchiori A, Mosena L, Prins MH, Prandoni P. The risk of recurrent venous thromboembolism among heterozygous carriers of factor V Leiden or prothrombin G20210A mutation. A systematic review of prospective studies. Haematologica, 2007, 92: 11071114.Schulman S. Current strategies in prophylaxis and treatment of venous thromboembolism. Ann Med, 2008, 40: 352-359.Schulman S. Current strategies in prophylaxis and treatment of venous thromboembolism. Ann Med, 2008, 40: 352-359.Bounameaux H, Perrier A. Duration of anticoagulation therapy for venous thromboembolism. Hematology Am Soc Hematol Educ Program, 2008: 252-258.Bounameaux H, Perrier A. Duration of anticoagulation therapy for venous thromboembolism. Hematology Am Soc Hematol Educ Program, 2008: 252-258.RuIz-GimInez N, SuЗrez C, GonzЗlez R, et al. Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism. Findings from the RIETE Registry. Thromb Haemost, 2008, 100: 26-31.RuIz-GimInez N, SuЗrez C, GonzЗlez R, et al. Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism. Findings from the RIETE Registry. Thromb Haemost, 2008, 100: 26-31.Kearon C, Akl E, Ornelas J et al. Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. Chest, 2016, 149(2): 315-352.Kearon C, Akl E, Ornelas J et al. Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. Chest, 2016, 149(2): 315-352.Garcia D. Novel anticoagulants and the future of anticoagulation. Thromb Res, 2009, 123(Supp 4): 50-55.Garcia D. Novel anticoagulants and the future of anticoagulation. Thromb Res, 2009, 123(Supp 4): 50-55.Garcia D, Libby E, Crowther MA. The new oral anticoagulants. Blood, 2010 115: 15-20.Garcia D, Libby E, Crowther MA. The new oral anticoagulants. Blood, 2010 115: 15-20.Arcelus J, Caprini J. Acute Deep Venous Thrombosis Prevention and Medical Treatment in book Rutherford's Vascular Surgery. 8th Edition Elsevier. 2014: 771-791Arcelus J, Caprini J. Acute Deep Venous Thrombosis Prevention and Medical Treatment in book Rutherford's Vascular Surgery. 8th Edition Elsevier. 2014: 771-791Mauro M, Ferraro G, Palmieri G. Profibrinolytic and antithrombotic effects of sulodexide:a double-blind, crossover, placebo-controlled study. Current Therapeutic Research, 1992, 51(3): 343350.Mauro M, Ferraro G, Palmieri G. Profibrinolytic and antithrombotic effects of sulodexide:a double-blind, crossover, placebo-controlled study. Current Therapeutic Research, 1992, 51(3): 343350.Lasierra C., Granado P. A study on the safety, efficacy, and efficiency of sulodexide compared with acenocoumarol in secondary prophylaxis in patients with deep venous thrombosis. Angiology, 2006, 57(1): 53-64.Lasierra C., Granado P. A study on the safety, efficacy, and efficiency of sulodexide compared with acenocoumarol in secondary prophylaxis in patients with deep venous thrombosis. Angiology, 2006, 57(1): 53-64.Errichi BM, Cesarone MR, Belcaro G et al. Prevention of recurrent deep venous thrombosis with sulodexide: the SanVal registry. Angiology, 2004, 55(3): 243-249.Errichi BM, Cesarone MR, Belcaro G et al. Prevention of recurrent deep venous thrombosis with sulodexide: the SanVal registry. Angiology, 2004, 55(3): 243-249.Andreozzi G, Bignamini A, DavY G et al. Sulodexide for the Prevention of Recurrent Venous Thromboembolism: The SURVET Study: A Multicenter, Randomized, Double-Blind, Placebo Controlled Trial. Circulation, 2015: CIRCULATIONAHA-115.Andreozzi G, Bignamini A, DavY G et al. Sulodexide for the Prevention of Recurrent Venous Thromboembolism: The SURVET Study: A Multicenter, Randomized, Double-Blind, Placebo Controlled Trial. Circulation, 2015: CIRCULATIONAHA-115.

The authors declare that there are no conflicts of interest present.